Company Overview and News

Rocky Brands (RCKY) Hits Fresh Highs: Is There Still Room to Run?

2018-04-27 zacks
Have you been paying attention to shares of Rocky Brands (RCKY - Free Report) ? Shares have been on the move with the stock up 12.6% over the past month. RCKY hit a new 52-week high of $24.45 in the previous session. Rocky Brands has gained 27.8% since the start of the year compared to the 0.5% move for the Consumer Discretionary sector and the 5.6% year-to-date return for its peer group.

Xtep International Holdings Ltd. ADR 2017 Q4 - Results - Earnings Call Slides

2018-03-16 seekingalpha
The following slide deck was published by Xtep International Holdings Ltd. ADR in conjunction with their 2017 Q4 earnings call.

Property tycoon Lee Shau-kee offloads another HK$75m worth of shares in Henderson Land

2017-12-24 scmp
The buying remained high while the selling among directors rose for the second straight week based on filings on the Hong Kong exchange from December 18 to 22.

Sportswear makers turn the corner after years of losses

2016-01-21 business.asiaone
International and domestic sportswear companies have finally turned the corner after being in recession for years. Sportswear majors posted strong growth in the China market in 2015, boosted by city dwellers' pursuit of a healthy lifestyle.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...